The U.S. Food and Drug Administration on Friday agreed to reconsider its recent decision barring drug compounders from ...

With the resolution, compounding pharmacies are no longer able to produce tirzepatide. And the FDA highlighted the point to ...

Poor purity can cause patients to experience fever, chills, nausea, skin irritation, infections and low blood pressure.

Some patients fear that they’ll lose access to tirzepatide because the US Food and Drug Administration determined that a ...

The U.S. Food and Drug Administration removed Eli Lilly's blockbuster weight-loss and diabetes drugs from its shortage list ...

Eli Lilly & Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the U.S., ...

Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

Ozempic is a drug for ... of average weight loss of 3.7% one year after starting on medications, the overall reported magnitude of benefit was less than in reported trials. The new study examines ...

Doctors are already using weight loss drugs to treat binge eating disorder. But some experts warn that it’s a Band-Aid, not a ...

A highly effective class of weight loss drug has taken the world by storm, as medications like Ozempic, Wegovy, and Zepbound become household names. These drugs, originally meant to treat diabetes, ...

The average workplace health insurance plan costs more than $25,000 amid rising prices and expensive weight-loss drugs such ...

The FDA declared the end to shortages of Zepbound and Mounjaro. That could mean new restrictions on pharmacies making ...